

**CORONA Remedies Limited**

(Formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059. Gujarat, India.

Tele.: + 079 - 40233000

Online at : Info@coronaremedies.com

website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

May 28, 2026

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
(BSE Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (E), Mumbai- 400051
(NSE Script Code: CORONA)

Dear Sir / Madam,

Sub.: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

We are pleased to inform that pursuant to the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has received EU-GMP Compliance Certification for its Hormone manufacturing facility and renewed EU-GMP approval for its Oral Solid Dosage (OSD) manufacturing facility at Bhayla, Ahmedabad, following an EUDRA GMP inspection that was conducted in April 2026.

A Press Release in the matter is enclosed herewith.

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For CORONA Remedies Limited

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a



PRESS RELEASE

Corona Remedies Accelerates India and World Market Expansion with EU-GMP Accreditations for Hormone and Oral Solid Dosage Facility

May 28, 2026, Ahmedabad, India : CORONA Remedies Limited, a leading India-focused pharmaceutical company with a strong presence across Women's Healthcare, Cardio-Diabeto, Pain Management and Urology therapies have received European Union Good Manufacturing Practice (EU-GMP) Compliance Certification for its Hormone manufacturing facility and renewed EU-GMP approval for its Oral Solid Dosage (OSD) manufacturing facility at Bhayla in Ahmedabad.

These significant milestones further strengthen CORONA's global manufacturing and quality credentials, reaffirming its commitment to world-class quality systems, scientific excellence, and manufacturing capabilities aligned with international standards.

Achieved with exceptional speed, these accreditations reflect CORONA's strong quality culture, robust compliance framework, and operational excellence, marking a defining step in its journey to become a globally trusted partner in Hormone & other therapies.

Commenting on the same, Mr. Viral Sitwala, Executive Director, CORONA Remedies Limited said,

*"We view this accreditation as a reflection of our unwavering commitment to quality and our philosophy of **"One World. One Quality."** By adopting uniform global practices, we aim to serve both the Indian market and other regulated/semi-regulated markets from this facility.*

*Backed by strong scientific expertise, rapidly expanding manufacturing capabilities, and a clear strategic vision, we remain committed to advancing accessible, high-quality healthcare in India while taking our Hormone portfolio to global markets — driven by our belief: **"THINK HORMONE... THINK CORONA."***



About CORONA Remedies Limited

Founded in 2004, CORONA Remedies Limited is the India's fastest growing pharmaceutical companies amongst Top 30 Pharmaceutical corporates, engaged in developing, manufacturing, and marketing products across key therapeutic areas including women's healthcare, cardio-diabetes, pain management, and urology. The Company operates WHO-GMP/EU GMP-certified manufacturing facilities and maintains strong innovation capabilities through DSIR-approved R&D centres.

Safe Harbour Statement:

Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management 's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

For further details please contact:

Company	Investor Relations Advisors
CORONA Remedies Limited CIN: L24231GJ2004PLC044656 Ms. Chetna Dharajiya – Company Secretary & Compliance Officer Email Id: investors@coronaremedies.com	Strategic Growth Advisors Pvt Ltd. CIN: U74140MH2010PTC204285 Mr. Sagar Shroff / Mr. Tanay Shah Email Id: sagar.shroff@sgapl.net / tanay.shah@sgapl.net Tel. No.: +91 98205 19303 / +91 98333 91899